SCHEMBL4977919

SCHEMBL4977919

Cc1ccc2c(c1)C1(NC(=O)N(Cc3ccccc3C(F)(F)F)C1=O)C(=O)N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
KDM4E B2RXH2 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
ATM Q13315 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 3/20 0.39
GAA P10253 3/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CHRM5 P08912 1/20 0.38
POLB P06746 1/20 0.37
AR P10275 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
C5AR1 P21730 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4267172 0.82 CHRM5 (0.42) KMT2AKDM4ENPSR1ATMTDP1
SCHEMBL4976844 0.80 KMT2A (0.38) KMT2ACYP3A4CYP2C19POLBPTGDR2
SCHEMBL4977915 0.78 KDM4E (0.42) KMT2AKDM4ENPSR1ATMTDP1
SCHEMBL2484248 0.73 PTGDR2 (0.64) KMT2AMEN1ALDH1A1GAAPOLB
SCHEMBL4974510 0.73 CNR1 (0.49) KMT2AKDM4ENPSR1MEN1ALDH1A1
SCHEMBL4979616 0.72 KMT2A (0.37) KMT2AKDM4EMEN1ALDH1A1CYP3A4
SCHEMBL4979166 0.72 CYP1A2 (0.39) KMT2AKDM4EMEN1ALDH1A1GAA
SCHEMBL4979426 0.72 CNR1 (0.51) KMT2AMEN1ALDH1A1CYP3A4CYP2C19
SCHEMBL4979970 0.72 AKR1B1 (0.41) KMT2AMEN1ALDH1A1GAACYP3A4
SCHEMBL20989112 0.72 CYP2C19 (0.54) KMT2AKDM4ENPSR1ATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984374-A1 USE OF SPIRO Ý IMIDAZOLIDINE-4, 3'-INDOLE¨2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 AstraZeneca AB (SE) 2008-10-29 EP claimed
WO-2007091946-A1 USE OF SPIRO [ IMIDAZOLIDINE-4, 3'-INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 WO claimed